Fonar Corp stock (US3444371021): Q3 earnings decline amid going-private proposal

Fonar Corp released its fiscal third quarter 2026 earnings on May 11, 2026, showing a revenue decline to $26.5 million from $27.2 million year-over-year, alongside net income dropping to $2.3 million and diluted EPS to $0.24 per share, according to StockTitan as of 05/11/2026. The results cover the quarter ended March 31, 2026. Concurrently, the company advanced a going-private transaction led by its CEO, proposing $19 per share.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

Fonar Corp: core business model

Fonar Corp, inventor of the first MRI scanner, operates diagnostic imaging centers primarily in the US, generating most revenue from patient scans using its proprietary Open MRI technology. The company also manufactures and services MRI equipment through a separate segment. For the nine months ended March 31, 2026, operations produced net revenue of $78.1 million, up slightly from $77.1 million prior year, per StockTitan SEC filing summary as of 05/11/2026.

This dual model supports steady cash generation, with $53.7 million in cash equivalents as of March 31, 2026, and a current ratio of 9.2. Stockholders' equity stood at $178.6 million, reflecting financial stability despite quarterly profit pressures.

Main revenue and product drivers for Fonar Corp

Revenue primarily stems from service fees at imaging centers, which accounted for the bulk of operating income in Q3 fiscal 2026. MRI scans represent the core offering, benefiting from Fonar's upright, open MRI systems designed for patient comfort. Nine-month revenue growth to $78.1 million was driven by volume in these centers, offsetting manufacturing segment losses, as reported in the May 11 earnings release via StockTitan as of 05/11/2026.

Key metrics include quarterly revenue of $26.5 million and nine-month net income attributable to FONR of $6.0 million, down from $7.6 million year-ago. The stock closed at $18.84 on May 11, 2026, on Nasdaq, near its 52-week high of $18.95, according to MarketBeat as of 05/11/2026.

Industry trends and competitive position

The diagnostic imaging sector sees demand growth from aging US populations and rising outpatient procedures, where Fonar Corp holds a niche with its patented upright MRI tech. Competitors include larger players like GE Healthcare, but Fonar's focus on open systems appeals to claustrophobic patients and weight-challenged individuals, supporting its 20+ imaging sites.

Why Fonar Corp matters for US investors

As a Nasdaq-listed small-cap with US-centric operations, Fonar Corp offers exposure to healthcare services amid Medicare reimbursement dynamics key to American markets. Its $219.2 million in total assets and minimal debt position it as a stable play in medical tech for retail portfolios tracking regional healthcare trends.

Conclusion

Fonar Corp's Q3 fiscal 2026 results highlighted revenue stability at imaging centers but profitability declines from higher costs and segment weaknesses, as detailed on May 11, 2026. The proposed $19 per share going-private deal adds a strategic layer, trading near that level on Nasdaq. Investors monitor next earnings on May 14 and transaction progress for US healthcare exposure.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.